Aripiprazole lauroxil - Generic Drug Details

What are the generic drug sources for aripiprazole lauroxil and what is the scope of freedom to operate?

Aripiprazole lauroxil is the generic ingredient in two branded drugs marketed by Alkermes Inc and is included in two NDAs. There are twenty patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Aripiprazole lauroxil has one hundred and ninety-four patent family members in twenty-nine countries.

There are three drug master file entries for aripiprazole lauroxil. One supplier is listed for this compound.

Summary for aripiprazole lauroxil

International Patents:	194
US Patents:	20
Tradenames:	2
Applicants:	1
NDAs:	2
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	38
Clinical Trials:	7
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for aripiprazole lauroxil
What excipients (inactive ingredients) are in aripiprazole lauroxil?	aripiprazole lauroxil excipients list
DailyMed Link:	aripiprazole lauroxil at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for aripiprazole lauroxil

Constraining patent/regulatory exclusivity:

11,097,006

Dosage:

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Constraining patent/regulatory exclusivity:

10,016,415

Dosage:

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for aripiprazole lauroxil

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Miami	Phase 4
University of California, Los Angeles	Phase 4
Alkermes, Inc.	Phase 4

See all aripiprazole lauroxil clinical trials

Pharmacology for aripiprazole lauroxil

Drug Class

Atypical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for aripiprazole lauroxil

N05AX	Other antipsychotics
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for aripiprazole lauroxil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes	11,969,469		Y
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-002	Oct 5, 2015		RX	Yes	No	9,526,726		Y
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes	11,406,632
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-001	Oct 5, 2015		RX	Yes	No	10,112,903			Y
Alkermes Inc	ARISTADA INITIO KIT	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	209830-001	Jun 29, 2018		RX	Yes	Yes	10,112,903			Y
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes	10,112,903			Y
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes	9,452,131

International Patents for aripiprazole lauroxil

Country	Patent Number	Title	Estimated Expiration
Japan	6546896
Israel	296695
New Zealand	597107	Heterocyclic compounds for the treatment of neurological and psychological disorders
Japan	2018090629	貯蔵安定性が改善された医薬組成物 (PHARMACEUTICAL COMPOSITIONS HAVING IMPROVED STORAGE STABILITY)
Croatia	P20161549
New Zealand	597108	Prodrugs of nh-acidic compounds
Russian Federation	2017108204	КОМПОЗИЦИИ ПРОЛЕКАРСТВА АРИПИПРАЗОЛА

Supplementary Protection Certificates for aripiprazole lauroxil

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0367141	SPC/GB04/039	United Kingdom		PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604
1675573	92427	Luxembourg		PRODUCT NAME: ARIPIPRAZOLE
1675573	300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
1675573	C300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
1675573	2014C/029	Belgium		PRODUCT NAME: ARIPIPRAZOLE; AUTHORISATION NUMBER AND DATE: EU/1/13/882 20131119

Aripiprazole Lauroxil: Market Dynamics and Financial Trajectory

Last updated: April 23, 2026

Aripiprazole lauroxil (AL; brand: Aristada) is an injectable, extended-release atypical antipsychotic used for schizophrenia and maintained treatment in patients stabilized on oral antipsychotics or other antipsychotics. Financial performance is driven by (1) dosing mix between initiation and maintenance regimens, (2) site-of-care execution and payer coverage of long-acting injectables (LAIs), (3) formulary preference versus competing LAIs, and (4) ongoing patent-driven and lifecycle competition from other LAIs rather than from direct short-cycle generics.

What drives the market dynamics for aripiprazole lauroxil?

1) LAI category tailwinds and schizophrenia treatment pattern

Aripiprazole lauroxil competes in the LAI segment where payers balance adherence benefits against higher per-dose acquisition costs. LAI adoption is shaped by:

• Dosing convenience (monthly to longer intervals depending on product and regimen)
• Medication persistence (reduced missed doses relative to oral therapy)
• Payer tools (step edits, prior authorization, and “preferred LAI” lists)

This category dynamic typically favors agents that can be positioned with clear initiation pathways and reliable administration workflows.

2) Competitive landscape within LAIs

In schizophrenia maintenance, LAI competition clusters around established brands with strong payer access. Aripiprazole lauroxil’s competitive posture depends on:

• Formulary tier placement
• Copay support availability
• Budget impact models used by PBMs
• Therapeutic equivalence perceptions among LAIs

The segment is not purely price-driven; it is driven by payer placement and administration logistics.

3) Product line mix: initiation and maintenance

Aripiprazole lauroxil is sold as a platform with multiple dosing options that create revenue sensitivity to:

• Patient conversion from other LAIs
• Adoption of longer-interval regimens
• Dose adherence to label-recommended schedules

Revenue trajectory typically improves when conversion flows stabilize and when prescriber and clinic workflows reduce missed visits.

4) Patent and exclusivity lifecycle

The market for AL is influenced by patent status across jurisdictional families and the pace of generic or biosimilar-like competition. In LAIs, entry risk tends to be concentrated at:

• Primary composition-of-matter and formulation patents
• Use and method-of-use patents
• Specific dosing/regimen patents and packaging/process claims

The absence of large-scale generic substitution for many LAI brands delays price erosion compared with oral small molecules, which changes the shape of the financial curve.

How does its financial trajectory typically evolve post-launch and during lifecycle competition?

Revenue shape mechanics in LAIs

Aripiprazole lauroxil’s financial trajectory generally follows a recognizable LAI pattern:

1. Adoption phase: penetration grows as prescribers incorporate the LAI into maintenance plans and clinics build administration capacity.
2. Conversion phase: revenue scales with patient switching from oral and from competing LAIs.
3. Maturation phase: growth becomes slower and depends on formulary stability.
4. Lifecycle pressure: entry of competitors (or increased formulary pressure) drives discounting and net-to-gross changes.

Key point for AL: LAI category dynamics can keep net revenue resilient longer than oral antipsychotics because substitution is more operational than retail-driven.

Net sales and profitability drivers

For a commercial injectable LAI, financial results are usually shaped by:

• Net pricing after rebates/discounts (PBM leverage, managed care mix)
• Growth in covered lives with access (formulary positioning)
• Administration adherence (missed visits reduce reimbursable doses)
• Manufacturing throughput and cold-chain costs (impact on margins)

What does the competitive and payer environment imply for aripiprazole lauroxil revenue durability?

Payer coverage is the gating factor

In LAIs, the dominant variable is not only clinical profile but coverage access. Payers often:

• Prefer a smaller set of LAIs as “preferred” within a therapeutic class
• Apply prior authorization and step edits
• Use budget impact to shift uptake between brands

Aripiprazole lauroxil’s revenue durability therefore tracks formulary stability more than it tracks raw market size.

Discounting pressure tends to rise when alternatives gain preferred status

When competitors secure preferred access, companies typically respond with:

• Higher rebate offers
• Greater patient support
• Contracting adjustments with major accounts

These pressures can compress net price even when prescription volumes remain stable.

Where does financial performance typically concentrate in the product’s regimen?

Initiation and conversion

For LAIs, early use and “conversion” to maintenance regimens matter because they determine:

• The speed of uptake after prescribing
• Patient retention through subsequent doses

If initiation pathways become harder due to payer controls, revenue can shift downward even if demand exists clinically.

Maintenance dosing intervals

Revenue also depends on the fraction of patients receiving longer-interval maintenance regimens versus more frequent schedules. Higher uptake of longer-interval options can:

• Reduce dosing “visit friction”
• Improve persistence
• Improve predictability of administration revenue

The net impact depends on the realized price and payer mix.

Key market takeaways for decision-making

Implications for R&D and portfolio strategy

• AL’s market is governed by LAI category adoption and formulary access more than by generic substitution mechanics.
• Competitive pressure is likely to be payer-mediated, with revenue sensitivity to preferred-list positioning and contracting.
• Lifecycle success depends on maintaining administration and coverage workflows that support persistence and conversion.

Implications for investment underwriting

• Model revenue using a framework that separates volume growth from net price (rebate pressure).
• Capture payer shifts as a primary driver of margin and net sales volatility.
• Treat the LAI segment as having delayed price erosion relative to oral generics, with sharper impacts around major access changes or competitive preference shifts.

Key Takeaways

• Aripiprazole lauroxil’s market dynamics are driven by LAI category behavior, payer coverage access, and persistence tied to administration workflows.
• Financial trajectory in LAIs typically follows adoption, conversion, maturation, then payer and competitive lifecycle pressure.
• Revenue durability depends on preferred formulary placement, discounting/rebate intensity, and patient retention rather than retail demand signals.

FAQs

1) What is the primary market driver for aripiprazole lauroxil?
Formulary access and payer coverage that determines whether prescribers and clinics can maintain consistent dosing.

2) How does competition typically impact LAI sales for aripiprazole lauroxil?
Through preferred-list status and contracting that can shift net pricing via rebates and reduce uptake even when clinical demand exists.

3) Why does initiation matter for aripiprazole lauroxil revenue?
Because conversion from oral or other LAIs into maintenance regimens determines the install base and future dosing continuity.

4) Is aripiprazole lauroxil financial performance more volume- or price-driven?
Both, but in practice net pricing and rebates rise when competitors gain access; volume depends on persistence and payer constraints.

5) What underwriting variable best predicts persistence effects?
Dose adherence driven by administration workflow and coverage continuity across dosing intervals.

---

References

[1] FDA. “Aristada (aripiprazole lauroxil) prescribing information.” U.S. Food and Drug Administration.
[2] FDA. “Aristada Initio (aripiprazole lauroxil) prescribing information.” U.S. Food and Drug Administration.
[3] U.S. Patent and Trademark Office. Patent full-text and bibliographic data for aripiprazole lauroxil-related patent families.